Delivery Order SPE2DB22D3004-SPE2DB26FQ90E
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on October 28, 2025, for the supply of Pertzye (pancrelipase) capsules—16,000 units in 100-count bottles. This competitive, non-set-aside contract has a ceiling value of $5,750.73 and a firm fixed price structure, with an ultimate completion date of October 29, 2025. The contract is performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,946.55 to AmerisourceBergen Drug Corp for 16,000 unit capsules of Pertzye DR 100s. This is a firm fixed price, non-set-aside contract awarded on August 4, 2025, with an ultimate completion date of August 5, 2025. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Pertzye (pancrelipase) capsules, 16,000 units at 100s strength, with a contract value of $44,349.27. This is a firm fixed price delivery order with an ultimate completion date of June 11, 2025, issued on June 10, 2025. The award was made through open competition with no set-aside designation. Performance will be conducted at the contractor's corporate office location in Conshohocken,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider based in Conshohocken, Pennsylvania. The $9,016.84 firm fixed-price delivery order is for the supply of 24,000 units of the pharmaceutical product Pertzye DR 24,000 Unit Capsule. This award is not designated as a set-aside contract. The contract has an ultimate completion date of June 6, 2025 and was awarded on June 5,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of 24,000 unit capsules of the drug Pertzye, with a ceiling value of $9,416.10 and a completion date of February 5, 2025. The contract is a firm fixed-price delivery order, and there was no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award, valued at $13,179.68, was made by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a pharmaceutical distribution company. The contract, with an ultimate completion date of October 12, 2023, is for the delivery of 8,000 units of the medication Pertzye DR capsules. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which does business as Amerisourcebergen. This contract is part of a larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 24,000 unit capsules of PERTZYE DR with a ceiling value of $20,343.60. This contract was competitively awarded without set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 15, 2025. The order will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The $31,234.56 firm fixed-price contract is for the delivery of 16,000 units of the drug Pertzye DR 250S capsules. The contract has a completion date of November 15, 2023 and was awarded on November 14, 2022. This delivery order is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $12,309.96 firm-fixed-price delivery order contract is for the supply of 24,000 unit capsules of the medication PERTZYE DR. The contract has an ultimate completion date of December 19, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The contract is for the delivery of 16,000 units of the pharmaceutical product Pertzye DR Capsule, with a total ceiling value of $23,802.53. The delivery order has a firm fixed price pricing type and is set to be completed by February 9, 2024. This award is not designated with any set-aside requirements, indicating full and open...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB26FQ90EDelivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a competitively awarded delivery order from the Defense Logistics Agency valued at $10,076.37 for 24,000 unit capsules of Pertzye (pancrelipase) with an 80-strength formulation. The contract, awarded on November 6, 2025, with a completion date of November 7, 2025, operates under a firm fixed-price structure and is not designated as a set-aside contract. This delivery order is a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. This award demonstrates AmerisourceBergen's continued role as a critical vendor within the Defense Logistics Agency's Medical Supply Chain, supplying pharmaceutical products to support military and veteran healthcare systems. Pertzye is a pancreatic enzyme replacement therapy used to treat pancreatic insufficiency, reflecting the company's extensive portfolio of specialty medications delivered through its federal contract awards. The rapid turnaround between award and completion dates indicates this represents an urgent medical supply need within the federal healthcare system served by the Defense Health Agency and other government entities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.1k | 11/6/25 |